-
J Clin Oncol: Consolidation and maintenance treatment for newly diagnosed multiple myeloma patients
Time of Update: 2021-09-29
The use of VRD for consolidation therapy can significantly improve the PFS and the depth of remission in newly diagnosed multiple myeloma patients compared with the maintenance therapy of nallidomide.
-
Can blood samples be collected on the patient's infusion side?
Time of Update: 2021-09-29
So, can the nurse collect blood samples from the indwelling needle on the infusion side of the patient?
-
Nature Sub-Journal: After recovering, still immunodeficiency, what does the new coronavirus do to B cells?
Time of Update: 2021-09-29
These results indicate that SARS-CoV-2 infection may change the metabolic activity of b cells and increase the production of ROS, thereby reducing the expression of CD19 and bcr-dependent signal transduction .
-
After infusing a bag of liquid, why does a hypokalemia patient become hyperkalemia?
Time of Update: 2021-09-29
After the incident, Xiao Zhao and the head nurse frank everything and conducted a deep review at the department meeting.
Cultivate the nurse's spirit of being self-consciousThe root cause of this incident is that Xiao Zhao was not serious about his work.
-
INT J LAB HEMATO: Peripheral granular lymphopenia and malformed leukocytosis as simple prognostic markers for COVID-19
Time of Update: 2021-09-29
The distribution of red blood cells in severe cases was significantly higher than that in mild cases ( P <.
The distribution of red blood cells in severe cases was significantly higher than that in mild cases ( infection P P <.
-
Blood: Molecular classification can improve the risk assessment of BCR-ABL1-negative B-ALL adult patients
Time of Update: 2021-09-29
Central point: Genetic testing can improve the risk allocation of most adult patients with BCR-ABL1-B-ALL; when combined with genotype consideration, antigen profile can affect the outcome of B-ALL patients .
5% of patients with good outcomes (5-year OS: 65%-80%) were considered standard risk (DUX4 rearrangement: 9.
-
Clin Cancer Res: Patients with multiple myeloma can safely use bridging radiotherapy for CAR T cell therapy!
Time of Update: 2021-09-29
Chimeric antigen receptor (CAR) T cells (CART-BCMA) targeting B cell maturation antigen (BCMA) is a promising method for the treatment of relapsed/refractory multiple myeloma (r/rMM)Patients with r/rMM often require radiotherapy (RT) to relieve symptoms .
-
Lancet Haemat: Long-term prognosis of Bentuximab combined with chemotherapy in the treatment of stage III/IV classic Hodgkin’s lymphoma
Time of Update: 2021-09-29
In summary, after 5 years of follow-up, regardless of the status of PET-2, compared with the ABVD regimen, the A+AVD regimen showed a strong and lasting improvement in the progression-free survival rate of stage III or IV classic Hodgkin’s lymphoma.
-
HAEMATOLOGICA: Third-hand tobacco exposure regulates platelet function in the uterus in a gender-dependent manner
Time of Update: 2021-09-29
thrombusFigure 2: The effect of in-utero THS exposure on platelet physiology in exposed male and female mice compared with a control group exposed to clean air .
The data provides evidence that the negative health effects of THS exposure to pregnant women extend to "unexposed" offspring .
-
Which is more accurate, blood HCG or urine HCG?
Time of Update: 2021-09-29
Blood: A quantitative test of HCG in the blood of patients within a few days is often used to rule out ectopic pregnancy or to monitor after miscarriage .
-
Lancet Oncol: Maintenance therapy with daratumumab can significantly reduce the risk of disease progression and death in patients with multiple myeloma
Time of Update: 2021-09-29
The results of Part 1 of the CASSIOPEIA study showed that newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation (ASCT) were treated with daretuzumab, bortezomib, thalidomide, and dexamethasone (D- The depth of remission and progression-free survival of the VTd) regimen as an induction and consolidation treatment were significantly better than those of bortezomib, thalidomide, and dexamethasone (VTd) regimens .
-
Science Advances: Exercise can improve tumor-related anemia
Time of Update: 2021-09-29
Because the main metabolic remodeling caused by tumors can change the red blood cell environment, the researchers measured the levels of blood lactic acid, free fatty acids and triglycerides in the plasma of tumor mice, and the results showed that the levels of these three metabolites were greatly increased .
-
JAMA Oncol: Trends in mortality and life expectancy of patients receiving allogeneic blood or bone marrow transplantation in the past 40 years
Time of Update: 2021-09-29
This study aims to clarify the trends in life expectancy and cause-specific late mortality of patients undergoing allogeneic BMT in the past 40 years .
In the past 40 years, the late mortality rate of allogeneic BMT recipients has decreased; however, life expectancy has not returned to the level of ordinary people.
-
Nature Communications: Fat cells destroy the transformation process of acute lymphoblastic leukemia, which is conducive to tumor survival and persistence
Time of Update: 2021-09-29
Therefore, an article published by a foreign research team in the journal Nature Communications demonstrated the dynamic evolution of bone marrow (BM) fat cells in the pathogenesis and treatment of ALL .
Its dynamic evolution is from cell exhaustion in the niche of primary leukemia to a completely rebuilt state after induction of remission .
-
JAMA Oncol: Carfilzomib + lenalidomide + dexamethasone can effectively prevent high-risk smoking myeloma from progressing to multiple myeloma.
Time of Update: 2021-09-29
Smoldering myeloma refers to the diagnostic criteria for multiple myeloma , But the diagnosis of multiple myeloma with slow disease progression and no clinical symptomsThis study aims to evaluate the effect of carfilzomib, lenalidomide and dexamethasone (KRd) combined with lenalidomide maintenance therapy as an early intervention for high-risk smoking myeloma to identify minimal residual disease (MRD) The incidence of negative complete remission (CR) .
-
"Xingguang Yiyi-In-Depth Interpretation" Season 2 Online Conference
Time of Update: 2021-09-29
CAR-T CAR-T lymphoma lymphoma immune immune June 22, 2021, Fosun Kate CAR-T cell therapy drugs Yi Kaida ® ® (A Jilun game Injection) in the country formally approved in 38 countries and In the region, nearly 5000 patients used an overall response rate (ORR) of 83%, a complete response (CR) rate of 58%, a median overall survival (OS) of 25.
-
Lancet Oncol: Tisagenlecleucel for the long-term clinical prognosis of refractory/relapsed aggressive B-cell lymphoma
Time of Update: 2021-09-19
In summary, Tisagenlecleucel has shown long-lasting activity and controllable safety in adult patients with relapsed or refractory aggressive B-cell lymphoma .
Tisagenlecleucel has shown long-lasting activity and controllable safety in adult patients with relapsed or refractory aggressive B-cell lymphoma .
-
Lancet: CD3/CD20 dual anti-Epcoritamab, a new choice for relapsed/refractory B-cell non-Hodgkin's lymphoma!
Time of Update: 2021-09-19
The overall remission rate of patients with relapsed/refractory follicular lymphoma is as high as 90% (55-100), of which 50% are complete remissionsIn summary, Epcoritamab single-agent subcutaneous injection in the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma is safe and well tolerated, and it has shown preliminary anti-tumor activity , and it is worth continuing the phase 2/3 study Further verification .
-
The gospel of the Cilantro Party?
Time of Update: 2021-09-19
In summary , this study shows that the anti-leukemia activity of CSP extract comes from the synergistic anti-cancer effect of catechin and rutin molecules .
In summary , this study shows that the anti-leukemia activity of CSP extract comes from the synergistic anti-cancer effect of catechin and rutin molecules .
-
The initial treatment trial of pevonedistat combined with azacitidine as the treatment of rare bone marrow cancer failed
Time of Update: 2021-09-19
It is reported that the test was carried out in patients with high-risk myelodysplastic syndrome (HR-MDS), chronic monocytic leukemia (CMML), and hypomyelocytic acute myeloid leukemia (LB-AML), and evaluated the combination of pevonedistat and azacitidine Whether first-line treatment can improve EFS compared with azacitidine alone .
